Concert Pharmaceuticals has developed AVP-786 (CTP-786 or deuterated dextromethorphan) and reached a milestone under Avanir Pharmaceuticals collaboration. Avanir completed first of a two-stage pharmacokinetic study of AVP-786 in healthy ...
Tags: Concert Pharmaceuticals, Avanir Pharmaceuticals collaboration, AVP-786
Concert Pharmaceuticals has received US patent for CTP-499, its drug candidate being developed for the treatment of diabetic nephropathy. CTP-499 is a potential treatment developed on the basis of DCE Platform for diabetic nephropathy, a ...